JP2009537559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537559A5 JP2009537559A5 JP2009511181A JP2009511181A JP2009537559A5 JP 2009537559 A5 JP2009537559 A5 JP 2009537559A5 JP 2009511181 A JP2009511181 A JP 2009511181A JP 2009511181 A JP2009511181 A JP 2009511181A JP 2009537559 A5 JP2009537559 A5 JP 2009537559A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- compound
- alkyl
- phenyl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims description 88
- 150000001875 compounds Chemical class 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- -1 perfluoromethoxy Chemical group 0.000 claims description 40
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 10
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- BLQYDCSAHNCALS-UHFFFAOYSA-N 2-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-2,2-dimethoxyacetic acid Chemical compound COC(OC)(C(O)=O)C1=CC=CC(OCC=2C(=CC=CC=2C)C)=C1 BLQYDCSAHNCALS-UHFFFAOYSA-N 0.000 claims description 8
- LGCYCNSMVCUZJY-UHFFFAOYSA-N 4-(1,3-dioxan-2-yl)butanoic acid Chemical compound OC(=O)CCCC1OCCCO1 LGCYCNSMVCUZJY-UHFFFAOYSA-N 0.000 claims description 8
- HWDQPRIRTNVIAL-UHFFFAOYSA-N 4-(1,3-dioxolan-2-yl)butanoic acid Chemical compound OC(=O)CCCC1OCCO1 HWDQPRIRTNVIAL-UHFFFAOYSA-N 0.000 claims description 8
- IFXGMWPTSPFSIP-UHFFFAOYSA-N 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-4,4-dimethoxybutanoic acid Chemical compound OC(=O)CCC(OC)(OC)C1=CC=CC(OCC=2C(=CC=CC=2C)C)=C1 IFXGMWPTSPFSIP-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 208000010706 fatty liver disease Diseases 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 230000036269 ulceration Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- RDOXTESZEPMUJZ-UHFFFAOYSA-N COc1ccccc1 Chemical compound COc1ccccc1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74763806P | 2006-05-18 | 2006-05-18 | |
| PCT/US2007/068745 WO2007137008A2 (en) | 2006-05-18 | 2007-05-11 | Compounds for the treatment of metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009537559A JP2009537559A (ja) | 2009-10-29 |
| JP2009537559A5 true JP2009537559A5 (enExample) | 2011-05-19 |
Family
ID=38723959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009511181A Pending JP2009537559A (ja) | 2006-05-18 | 2007-05-11 | 代謝障害の処置のための化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7935689B2 (enExample) |
| EP (1) | EP2019673A4 (enExample) |
| JP (1) | JP2009537559A (enExample) |
| KR (1) | KR20090010035A (enExample) |
| CN (1) | CN101437506A (enExample) |
| AU (1) | AU2007253929B2 (enExample) |
| CA (1) | CA2651598A1 (enExample) |
| IL (1) | IL195203A0 (enExample) |
| MX (1) | MX2008014560A (enExample) |
| NZ (1) | NZ572681A (enExample) |
| WO (1) | WO2007137008A2 (enExample) |
| ZA (1) | ZA200808963B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2530235T3 (es) * | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| JP2009525982A (ja) * | 2006-02-02 | 2009-07-16 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009091732A1 (en) * | 2008-01-15 | 2009-07-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| TW201341356A (zh) * | 2012-02-28 | 2013-10-16 | 皮拉馬爾企業有限公司 | 作為gpr促效劑之苯基烷酸衍生物 |
| WO2015028960A1 (en) * | 2013-08-28 | 2015-03-05 | Piramal Enterprises Limited | Substituted heterocyclic derivatives as gpr agonists and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69209357D1 (de) * | 1991-05-09 | 1996-05-02 | Hoffmann La Roche | Substituierte Carbonsäurederivate |
| DE4122315A1 (de) * | 1991-07-05 | 1993-01-07 | Basf Ag | 2-aryl-2,2-dialkoxyessigsaeurealkylester, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von arylglyoxylsaeureester |
| FR2781222A1 (fr) * | 1998-07-17 | 2000-01-21 | Lipha | Composes cycliques utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procede de preparation |
| JP2002371033A (ja) * | 2001-04-10 | 2002-12-26 | Sankyo Co Ltd | ω−アリール−α−置換脂肪酸誘導体 |
| RU2341513C2 (ru) * | 2001-06-12 | 2008-12-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических заболеваний |
| CA2502297C (en) | 2002-11-01 | 2011-12-13 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| ES2530235T3 (es) | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| JP4847314B2 (ja) * | 2003-04-07 | 2011-12-28 | コーティカル・ピーティーワイ・リミテッド | 炎症性疾患を治療するための新規な方法 |
| ES2353601T3 (es) | 2003-04-15 | 2011-03-03 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos. |
| CN1777576A (zh) | 2003-04-22 | 2006-05-24 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CA2522738C (en) * | 2003-04-30 | 2011-11-08 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| MXPA06001963A (es) | 2003-08-20 | 2006-05-31 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de trastornos metabolicos. |
| WO2006127133A2 (en) | 2005-04-01 | 2006-11-30 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US7820721B2 (en) | 2006-01-25 | 2010-10-26 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| AU2007208127A1 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
-
2007
- 2007-05-11 CA CA002651598A patent/CA2651598A1/en not_active Abandoned
- 2007-05-11 KR KR1020087026318A patent/KR20090010035A/ko not_active Withdrawn
- 2007-05-11 NZ NZ572681A patent/NZ572681A/en not_active IP Right Cessation
- 2007-05-11 JP JP2009511181A patent/JP2009537559A/ja active Pending
- 2007-05-11 CN CNA2007800165233A patent/CN101437506A/zh active Pending
- 2007-05-11 EP EP07783635A patent/EP2019673A4/en not_active Withdrawn
- 2007-05-11 WO PCT/US2007/068745 patent/WO2007137008A2/en not_active Ceased
- 2007-05-11 MX MX2008014560A patent/MX2008014560A/es active IP Right Grant
- 2007-05-11 US US12/300,239 patent/US7935689B2/en active Active - Reinstated
- 2007-05-11 AU AU2007253929A patent/AU2007253929B2/en not_active Ceased
-
2008
- 2008-10-20 ZA ZA200808963A patent/ZA200808963B/xx unknown
- 2008-11-10 IL IL195203A patent/IL195203A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531280A5 (enExample) | ||
| JP2009528375A5 (enExample) | ||
| CA2513092A1 (en) | Compounds for the treatment of metabolic disorders | |
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2009528275A5 (enExample) | ||
| US6436938B1 (en) | Combination treatment for depression | |
| JP6238460B2 (ja) | 脂質異常症治療剤 | |
| JP2006524252A5 (enExample) | ||
| RU2008123000A (ru) | Соединения для лечения метаболических нарушений | |
| CA2521589A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2010501010A5 (enExample) | ||
| CN103102348B (zh) | 噁二唑类化合物及其制备方法、药物组合物及其用途 | |
| JP2007523155A5 (enExample) | ||
| RU2010141823A (ru) | Соединения и способ снижения мочевой кислоты | |
| JP2005526696A5 (enExample) | ||
| RU2006108572A (ru) | Соединения для лечения метаболических нарушений | |
| JP2004508399A5 (enExample) | ||
| CN1159305C (zh) | 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物 | |
| CA2502297A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2009524686A5 (enExample) | ||
| JP2009539877A5 (enExample) | ||
| JP2008530242A5 (enExample) | ||
| JP2004526721A5 (enExample) | ||
| US20020147206A1 (en) | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy |